Intranasal application of stem cells and their derivatives as a new hope in the treatment of cerebral hypoxia/ischemia: a review.

Salehi, Mohammad Saied; Jurek, Benjamin; Karimi-Haghighi, Saeideh; Nezhad, Nahid Jashire; Mousavi, Seyedeh Maryam; Hooshmandi, Etrat; Safari, Anahid; Dianatpour, Mehdi; Haerteis, Silke; Miyan, Jaleel A.; Pandamooz, Sareh; Borhani-Haghighi, Afshin

Based on the MRI, cell therapy was not able to significantly reduce the infarct size; however, treatment with MSCs provided protection from MBP degradation indicating attenuation of white matter loss 28 days after ischemia. Although reports on this method of cell delivery are mainly centered around the therapeutic consequences of the cell therapy, few studies focused on the pathways by which intranasally applied cells enter the brain. At day 28 post-stroke, the cell therapy had increased the number of EdU and BrdU-positive cells in the ipsilateral striatum, near the ischemic boundary zone, indicating an enhancement of endogenous cell proliferation. Beneficial potential of neural stem cells (NSCs) in cell therapy after ischemia Although MSCs are considered the most commonly employed stem cell type for cell-based therapies in general, and the field of cerebral hypoxia/ischemia in particular, the curative potential of NSC is gaining interest. Keywords: conditioned medium; hypoxic brain; ischemic brain; nasal delivery; secretome; stem cell EN conditioned medium hypoxic brain ischemic brain nasal delivery secretome stem cell 583 606 24 08/09/22 20220801 NES 220801 Introduction Cerebral ischemia and hypoxic brain damage are devastating conditions that are considered as major global problems.

CEREBRAL anoxia-ischemia; STEM cells; CEREBRAL anoxia; SMELL; VASCULAR cell adhesion molecule-1; DESPAIR; GLIAL fibrillary acidic protein; MESENCHYMAL stem cells

Reviews in the Neurosciences, 2022, Vol 33, Issue 6, p583

0334-1763

Academic Journal

10.1515/revneuro-2021-0163